octaplasLG
Last Updated on eMC 27-Jun-2017 View document | Octapharma Limited Contact details
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 27-Jun-2017 and displayed until Current
Reasons for adding or updating:
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 11-Jul-2016 and displayed until 27-Jun-2017
Reasons for adding or updating:
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 4 - possible side effects
- Change to section 5 - how to store
- Change to section 6 - date of revision
Updated on 31-May-2016 and displayed until 11-Jul-2016
Reasons for adding or updating:
- Change to section 3 - how to take/use
- Change to section 6 - date of revision
Updated on 08-May-2015 and displayed until 31-May-2016
Reasons for adding or updating:
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - use in children/adolescents
- Change to section 3 - how to take/use
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
Updated on 13-May-2014 and displayed until 08-May-2015
Reasons for adding or updating:
- New PIL for eMC ie a PIL for an existing product but one that is new to the eMC
Octapharma Limited
The Zenith Building, 26 Spring Gardens, Manchester, Lancashire, M2 1AB
+44 (0)161 837 3799
+44 (0)161 837 3770
0845 1300 522
+44 (0)161 837 3799
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue